TOOLGEN INCORPORATED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69,500 KRW | +9.11% |
|
+17.60% | -1.00% |
| 2023 | ToolGen Incorporated announced that it has received KRW 33 billion in funding | CI |
| 2023 | ToolGen Incorporated announced that it expects to receive KRW 33 billion in funding | CI |
| Sales 2022 | 743M 540K | Sales 2023 | 1.1B 801K | Capitalization | 556B 403M |
|---|---|---|---|---|---|
| Net income 2022 | -18.18B -13.2M | Net income 2023 | -42.34B -30.74M | EV / Sales 2022 | 511 x |
| Net cash position 2022 | 52.68B 38.24M | Net cash position 2023 | 64.54B 46.86M | EV / Sales 2023 | 445 x |
| P/E ratio 2022 |
-23.7
x | P/E ratio 2023 |
-13.1
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 76.85% |
More Fundamentals
* Assessed data
More news
| 1 day | +9.11% | ||
| 1 week | +17.60% | ||
| Current month | +2.36% | ||
| 1 month | +1.61% | ||
| 3 months | +33.40% | ||
| 6 months | +141.32% | ||
| Current year | -1.00% |
1 week
59 000.00
70 000.00
1 month
57 500.0074 500.00
Current year
45 550.00110 000.00
1 year
26 100.00110 000.00
3 years
26 100.00166 500.00
5 years
22 100.00166 500.00
10 years
22 100.00173 700.00
| Managers | Title | Age | Since |
|---|---|---|---|
Young-Ho Kim
CEO | Chief Executive Officer | 59 | - |
Byung-Hwa Lee
CEO | Chief Executive Officer | 56 | 19-09-03 |
Seok-Joong Kim
CTO | Chief Tech/Sci/R&D Officer | 48 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chang-Kyu Kim
BRD | Director/Board Member | 57 | - |
Il-Ho Ha
BRD | Director/Board Member | 65 | - |
Byung-Hwa Lee
CEO | Chief Executive Officer | 56 | 19-09-03 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 69,500 | +9.11% | 153,585 |
| 24-04-23 | 63,700 | +2.25% | 43,149 |
| 24-04-22 | 62,300 | +1.96% | 30,150 |
| 24-04-19 | 61,100 | +0.66% | 53,086 |
| 24-04-18 | 60,700 | +2.71% | 39,402 |
End-of-day quote Korea S.E., April 23, 2024
More quotes
ToolGen, Inc. is principally engaged in the development of engineered nucleases. The Companyâs main products portfolio consists of ribose nucleic acid (RNA)-guided endonucleases (RGEN) as well as deoxyribonucleic acid (DNA)-directed RGEN (dRGEN), which are applied as tools for editing genetic information in microbial, plant, animal and human cells. In addition, it is involved in the provision of genome engineering services.
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -1.00% | 400M | |
| +4.09% | 43.84B | |
| +47.81% | 41.25B | |
| +9.45% | 41.68B | |
| -10.92% | 27.04B | |
| +9.32% | 25.53B | |
| -24.87% | 18.18B | |
| +29.70% | 12.29B | |
| +1.28% | 12.29B | |
| +7.78% | 11.15B |
- Stock Market
- Equities
- A199800 Stock
